Core Viewpoint - The company, Chongqing Shanwaishan Blood Purification Technology Co., Ltd., has shown significant growth in revenue and net profit for the first nine months of 2025, indicating strong operational performance in the medical device sector [2]. Financial Performance - For the period from January to September 2025, the company achieved a revenue of 584 million yuan, representing a year-on-year growth of 39.79% [2]. - The net profit attributable to the parent company reached 104 million yuan, marking a year-on-year increase of 68.68% [2]. Stock Performance - As of October 30, the company's stock price decreased by 2.05%, trading at 16.26 yuan per share, with a total market capitalization of 5.225 billion yuan [1]. - Year-to-date, the stock price has increased by 47.02%, with a 11.91% rise over the last five trading days [1]. Shareholder Information - As of September 30, the number of shareholders increased to 10,300, a rise of 26.20% compared to the previous period [2]. - The average number of circulating shares per shareholder decreased by 20.76% to 22,805 shares [2]. Dividend Distribution - Since its A-share listing, the company has distributed a total of 104 million yuan in dividends [3]. Institutional Holdings - As of September 30, 2025, among the top ten circulating shareholders, Penghua Medical Technology Stock A is the fourth largest with 5.182 million shares, marking a new entry [3]. - Bosera Healthcare Mixed A remains the sixth largest shareholder, holding 3.257 million shares, unchanged from the previous period [3].

Group 1 - Chuanfa Longmang's wholly-owned subsidiary plans to invest 660 million yuan to establish a joint venture for a 175,000 tons/year high-pressure lithium iron phosphate project in Sichuan Mianzhu, with a total investment of 1.961 billion yuan [1] - The joint venture will be co-owned by Jiangxi Shenghua New Materials (51%) and Deyang Chuanfa Longmang (49%) [1] - Chuanfa Longmang specializes in the production and sales of various phosphate products, including lithium iron phosphate [1] Group 2 - Sino Medical's COMETIU self-expanding intracranial drug-coated stent system registration application was not approved by the National Medical Products Administration [2] - Sino Medical focuses on the research, development, production, and sales of high-end interventional medical devices [3] Group 3 - Jincheng Pharmaceutical's subsidiaries have been selected for the 11th batch of national drug centralized procurement [3] - Jincheng Pharmaceutical is engaged in the research, development, production, and sales of pharmaceutical intermediates and formulations [3] Group 4 - Zhongke Lanyun reported a 4.29% increase in revenue to 1.302 billion yuan and a 2.17% increase in net profit to 211 million yuan for the first three quarters [4] - The company specializes in wireless audio SoC chip research, design, and sales [5] Group 5 - Dabo Medical achieved a 22.69% increase in revenue to 1.876 billion yuan and a 77.03% increase in net profit to 425 million yuan for the first three quarters [6] - Dabo Medical focuses on the production, research, and sales of high-value medical consumables [7] Group 6 - Dayang Electric reported a 3.81% increase in revenue to 9.180 billion yuan and a 25.95% increase in net profit to 845 million yuan for the first three quarters [8][9] - The company operates in the electric motor sector, focusing on building and home appliance motors and automotive components [9] Group 7 - Fudan Microelectronics reported a 12.70% increase in revenue to 3.024 billion yuan but a 22.69% decrease in net profit to 330 million yuan for the first three quarters [10][11] - The company specializes in the design, development, and testing of large-scale integrated circuits [11] Group 8 - Shaanxi Energy reported a 2.83% decrease in revenue to 16.359 billion yuan and a 3.23% decrease in net profit to 2.417 billion yuan for the first three quarters [12][13] - The company is involved in thermal power generation and coal production and sales [13] Group 9 - Runhe Software reported a 12.86% increase in revenue to 2.719 billion yuan but a 29.01% decrease in net profit to 78.57 million yuan for the first three quarters [14][15] - The company focuses on financial technology, smart IoT, and smart energy [15] Group 10 - Shenzhen Gas reported an 8.63% increase in revenue to 22.528 billion yuan but a 13.08% decrease in net profit to 918 million yuan for the first three quarters [16][17] - The company specializes in urban gas supply and comprehensive energy services [17] Group 11 - Light Media reported a 150.81% increase in revenue to 3.616 billion yuan and a 406.78% increase in net profit to 2.336 billion yuan for the first three quarters [18][19] - The company is engaged in the investment, production, and distribution of film projects [19] Group 12 - Dazhong Mining's subsidiary obtained a mining license for the Hunan Jijiao Mountain lithium mine, with a resource amount of 490 million tons, equivalent to approximately 3.2443 million tons of lithium carbonate [19] - The company specializes in iron ore mining and production [19] Group 13 - Yirui Technology reported a 14.22% increase in revenue to 1.549 billion yuan and a 20.61% increase in net profit to 471 million yuan for the first three quarters [20] - The company focuses on the research, production, and sales of digital X-ray detectors and related solutions [20] Group 14 - TCL Zhonghuan reported a 4.48% decrease in revenue to 121.572 billion yuan and a net loss of 5.777 billion yuan for the first three quarters [21][22] - The company specializes in the research, production, and sales of photovoltaic silicon wafers, cells, and modules [22] Group 15 - Huangshan Tourism reported an 8.75% increase in revenue to 1.535 billion yuan but an 11.02% decrease in net profit to 253 million yuan for the first three quarters [23][24] - The company provides tourism and leisure services [24] Group 16 - Mountain Outside Mountain reported a 39.79% increase in revenue to 584 million yuan and a 68.68% increase in net profit to 105 million yuan for the first three quarters [25][26] - The company specializes in the research, production, and sales of blood purification equipment and services [26] Group 17 - Huajin Capital reported a 16.36% increase in revenue to 349 million yuan and a 185.62% increase in net profit to 104 million yuan for the first three quarters [27] - The company focuses on investment management and electronic device manufacturing [27] Group 18 - Datang Power reported a 1.82% decrease in revenue to 89.345 billion yuan but a 51.48% increase in net profit to 6.712 billion yuan for the first three quarters [28][29] - The company primarily engages in thermal power generation [29] Group 19 - Datang Power announced the acquisition of a 50% stake in Anhui Electric Power for 1 yuan, which will result in full ownership of Anhui Electric Power [30] - The company focuses on thermal power generation [30] Group 20 - Kairun Co. reported a 22.94% increase in revenue to 3.719 billion yuan but a 13.38% decrease in net profit to 278 million yuan for the first three quarters [31] - The company specializes in the research, design, production, and sales of leisure bags and related products [31] Group 21 - Dafu Technology reported a 1.95% increase in revenue to 1.764 billion yuan but a net loss of 170 million yuan for the first three quarters [32] - The company focuses on the research, production, and sales of RF products and automotive components [32] Group 22 - Dafu Technology plans to publicly transfer 49% of its stake in Dasheng Graphite [34] - The company specializes in the research, production, and sales of RF products and automotive components [34]

Core Insights - The company reported strong financial performance in Q3 and the first three quarters of the year, with significant year-on-year growth in revenue and net profit [1][2] Financial Performance - For the first three quarters, the company achieved revenue of 584 million yuan, a year-on-year increase of 39.79%, and a net profit attributable to shareholders of 104 million yuan, up 68.68% [1] - In Q3 alone, the company generated revenue of 227 million yuan, reflecting a 61.66% year-on-year growth, and a net profit of approximately 49.45 million yuan, which is a remarkable increase of 205.50% [1] - The net cash flow from operating activities reached 166 million yuan, a substantial increase of 156.79% compared to the previous year [1] Market Position - The company maintained a leading position in the blood purification equipment market, with a market share of 19.91% for blood dialysis machines, an increase of 7.01% year-on-year, and 18% for continuous blood purification equipment, up 3.56% year-on-year [1] Product Development and Strategy - The company is focusing on enhancing its research and development capabilities, with R&D investment reaching 18.21 million yuan, a 27.02% increase year-on-year [2] - The company aims to deepen its presence in the blood purification sector, prioritizing technological innovation as a core strategy and expanding its product line to cover the entire industry chain [2]

Core Viewpoint - The company, Shanwaishan (688410.SH), experienced a significant stock price increase of 11.78%, reaching a market value of 5.33 billion yuan, following the announcement of strong financial results for the third quarter [1] Financial Performance - The company's third-quarter revenue was 227 million yuan, representing a year-on-year growth of 61.66% [1] - The net profit for the third quarter was 49.45 million yuan, showing a substantial year-on-year increase of 205.50% [1] - For the first three quarters, the total revenue reached 584 million yuan, with a year-on-year growth of 39.79% [1] - The net profit for the first three quarters was 104 million yuan, reflecting a year-on-year increase of 68.68% [1] Shareholder Activity - In early September, major shareholder Dajiankang and director Ren Yingxiang planned to reduce their holdings by up to 4.08% of the company's shares [1] - The company has announced a total of six share reduction plans over the past three years [1]

Group 1 - The company has guaranteed the authenticity, accuracy, and completeness of the quarterly report, and assumes legal responsibility for any false records or misleading statements [2][3][4] - The company will not conduct an audit for the third-quarter financial statements [3][8] - The company has approved the repurchase and cancellation of 1,715,024 shares from the 2024 employee stock ownership plan due to unmet performance conditions [5][6] Group 2 - The company has proposed to appoint Tianzhi International Accounting Firm as the auditor for the 2025 fiscal year, pending approval from the shareholders' meeting [10][17][19] - Tianzhi International has a strong background in audit services, with a total revenue of 2.501 billion yuan in 2024, including 1.938 billion yuan from audit services [11][14] - The company plans to use up to 1 billion yuan of idle funds for cash management, focusing on safe and liquid financial products [27][32][36]

本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 证券代码：688410 证券简称：山外山 公告编号：2025-055 重庆山外山血液净化技术股份有限公司 关于召开2025年第三次临时股东大会的通知 2025年第三次临时股东大会 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 11 月 14 日 14 点 30 分 召开地点：重庆市两江新区慈济路 1 号 8 楼会议室 （五） 网络投票的系统、起止日期和投票时间。 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 股东大会召开日期：2025年11月14日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 东大会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通 过互联网投票平台的投票时间为股东大会 ...

Core Viewpoint - The company reported significant growth in both revenue and net profit for the third quarter of 2025, indicating strong financial performance and operational efficiency [1] Financial Performance - The company's operating revenue reached 227 million yuan, representing a year-on-year increase of 61.66% [1] - The net profit attributable to shareholders was 49.4488 million yuan, showing a substantial year-on-year increase of 205.50% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 43.3684 million yuan, reflecting a remarkable year-on-year increase of 236.47% [1]

本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 证券代码：688410 证券简称：山外山 公告编号：2025-051 重庆山外山血液净化技术股份有限公司（以下简称"公司"）第三届监事会 第十七次会议于 2025 年 10 月 28 日（星期二）在重庆市两江新区慈济路 1 号 8 楼会议室以现场会议的方式召开。会议通知已于 2025 年 10 月 23 日通过邮件的 方式送达各位监事。本次会议应出席监事 3 人，实际出席监事 3 人。 会议由监事会主席谢川先生主持，公司部分董事和高级管理人员列席会议。 会议召开符合有关法律、法规、规章和《公司章程》的规定。出席会议的监事对 各项议案进行了认真审议并做出了如下决议： 二、监事会会议审议情况 （一）审议通过《关于公司 2025 年第三季度报告的议案》 经审查，监事会认为：董事会编制和审议公司 2025 年第三季度报告的程序 符合法律、行政法规及中国证监会的规定，报告内容真实、准确、完整地反映了 公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 ...

Core Insights - The company reported a significant increase in both revenue and net profit for the third quarter of 2025, indicating strong financial performance [1] Financial Performance - The company's third-quarter revenue reached 227 million, representing a year-on-year growth of 61.66% [1] - The net profit for the third quarter was 49.44 million, showing a remarkable year-on-year increase of 205.5% [1] - For the first three quarters of 2025, the total revenue was 584 million, which is a year-on-year growth of 39.79% [1] - The net profit for the first three quarters amounted to 104 million, reflecting a year-on-year increase of 68.68% [1] Market Position - The company has seen a continuous increase in market share, which has contributed to the steady growth in sales revenue of blood purification equipment [1] - There has been a significant rise in sales revenue from the company's self-produced blood purification consumables [1]

Group 1 - The core viewpoint of the article highlights the significant growth in revenue and net profit for the company in the third quarter and the first three quarters of the year [1] Group 2 - The company's third-quarter revenue reached 227 million yuan, representing a year-on-year increase of 61.66% [1] - The net profit for the third quarter was 49.448 million yuan, showing a year-on-year growth of 205.50% [1] - For the first three quarters, the total revenue amounted to 584 million yuan, with a year-on-year increase of 39.79% [1] - The net profit for the first three quarters was 104 million yuan, reflecting a year-on-year growth of 68.68% [1]